Company: PTHS
Filing Date: 2025-05-09
Form Type: PREM14C
Source: 0001140361-25-018219
Chunk: 52

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-09
Form: PREM14C
Chunk 52
---
 planned pivotal clinical trials; |

| • | the potential development and the filing on an Investigation New Drug (“IND”) application for other future compounds; |

| • | the initiation, scope, progress, timing, costs and results of drug discovery, laboratory testing, manufacturing, preclinical studies and clinical trials for any other future compounds that Channel may pursue in the future, if any; |

| • | the outcome, timing and costs of seeking regulatory approvals; |

| • | the costs associated with the manufacturing process development and evaluation of third-party manufacturers; |

| • | the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, in the event Channel receives marketing approval for CC8464, CT2000, CT3000 or any other future compounds Channel may develop; |

| • | the extent to which the costs of future compounds, if approved, will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors; |

| • | the costs of commercialization activities for CC8464, CT2000, CT3000 and other future compounds if Channel receives marketing approval for CC8464, CT2000, CT3000 or any other future compounds it may develop, including the costs and timing of establishing product sales, medical affairs, marketing, distribution and manufacturing capabilities; |

| • | subject to receipt of marketing approval, if any, revenue received from commercial sale of CC8464, CT2000, CT3000 or any of its other future compounds; |

| • | the terms and timing of any future collaborations, licensing, consulting or other arrangements that Channel may establish; |

| • | the amount and timing of any payments Channel may be required or decide to make, or that it may receive, in connection with the licensing, filing, prosecution, maintenance, and enforcement of any patents or other intellectual property rights and defense against third party intellectual property infringement claims, including milestone and royalty payments and patent prosecution fees that it is obligated to pay pursuant to its license agreements, if any; |

| • | the development of alternative treatments for EM or iSFN or other pain indications; |

28

TABLE OF CONTENTS

| • | its ability to establish and maintain collaborations and licenses on favorable terms, if at all; and |

| • | the extent to which it acquires or in-license other compounds and technologies. |

Identifying potential compounds and conducting preclinical testing and